close Icon

Identifying risk factors and biomarkers of post-acute sequelae COVID-19 (PASC, Long COVID)

After acute COVID-19, some people develop post-acute sequelae COVID, (PASC, commonly known as Long COVID).  People with PASC experience persistent symptoms post-COVID and often develop new symptoms which can last for many months or even years. PASC presents with both general and multisystem symptoms including but not limited to fatigue, fever, myalgia, pulmonary and cardiovascular symptoms, neurological diseases and digestive issues.  Currently, there is no specific diagnostic test/s for PASC due to its diverse presentation and complexity.

To understand the risk factors of developing PASC in different populations and to identify biomarkers of disease.

2023–⁠ongoing

We are performing a clinical research study assessing the impact of COVID-19 infection outcomes in People living without a functioning spleen.  This includes reporting on COVID-19 infections, hospitalisation and PASC/Long COVID.  We will apply this approach to other cohorts to compare different risk factors.  We will also recruit participants who have PASC/Long COVID to screen for biomarkers of disease.

Identifying who is at risk of developing PASC/Long COVID and biomarkers of PASC are essential to improve diagnosis, inform patient care and improve quality of life.

Contactburnet

Doctor Gabriela Khoury

Contact Doctor Gabriela Khoury for more information about this project. 

EMAIL

Partners +
Collaborators

  • Monash Health: A/Prof Ian Woolley
  • Spleen Australia: Penny Jones